Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 20.54 USD 1.38% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Bicycle Therapeutics PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bicycle Therapeutics PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Bicycle Therapeutics PLC
NASDAQ:BCYC
Revenue
$36.9m
CAGR 3-Years
46%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Revenue
$6.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Revenue
ÂŁ20.1m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Revenue
$1.7m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Revenue
ÂŁ249.4m
CAGR 3-Years
102%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Revenue
ÂŁ668.8m
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
6%
No Stocks Found

Bicycle Therapeutics PLC
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.

BCYC Intrinsic Value
10.81 USD
Overvaluation 47%
Intrinsic Value
Price

See Also

What is Bicycle Therapeutics PLC's Revenue?
Revenue
36.9m USD

Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Revenue amounts to 36.9m USD.

What is Bicycle Therapeutics PLC's Revenue growth rate?
Revenue CAGR 5Y
31%

Over the last year, the Revenue growth was 49%. The average annual Revenue growth rates for Bicycle Therapeutics PLC have been 46% over the past three years , 31% over the past five years .

Back to Top